This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Agrisera
product type :
antibody
product name :
WRKY22 WRKY transcription factor 22
catalog :
AS16 3830
quantity :
100 µl
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
application :
western blot
product information
Product number :
AS16 3830
Product name :
WRKY22 WRKY transcription factor 22
Immunogen :
KLH-conjugated synthetic peptide chosen from Oryza sativa protein sequence UniProt: Q8SA13; LOC_Os01g60490.1
Host :
Rabbit
Clonality :
Polyclonal
Purity :
Serum
Format :
Lyophilized
Quantity :
100 µl
Tested applications :
Western blot (WB)
Related products :
antibodies to proteins involved in regulation of transcription antibodies to other proteins from Oryza sativa
Recommended dilutions :
1 : 1000 (WB)
Expected apparent MW :
29.8 30 kDa
Confirmed reactivity :
Oryza sativa
Not reactive in :
No confirmed exceptions from predicted reactivity are currently known.
Selected references :
To be added when available, antibody released in April 2016.
Background :
WRKY transcription factor 22 belongs to superfamily of TFs with WRKY and zinc finger domains.
Reconstitution :
For reconstitution add 100 µl of sterile water.
Storage :
Store lyophilized/reconstituted at -20°C; make aliquots to avoid repeated freeze-thaw cycles.
UniProt number :
Q8SA13
company information

Agrisera
Agrisera is a Swedish company specializing in polyclonal and monoclonal antibody production, offering primary and secondary antibodies off-the-shelf. Agrisera offers an extensive list of antibodies suitable for detection of plant and algal proteins in a wide range of research areas and applications. They are reactive in thousands of plant and algal species and cited in thousands of scientific articles. Agrisera was awarded as the Plant Science Antibody Supplier of the Year by CiteAB for the company with the most antibody citations for research related to plant science during 2018.
questions and comments